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Review
Ongoing exposures to toxic chemicals such 
as arsenic continue to pose a significant 
threat to public health. The World Health 
Organization (WHO) estimates that > 200 
million persons worldwide might be chroni-
cally exposed to arsenic in drinking water at 
concentrations above the WHO safety stan-
dard of 10 µg/L (WHO 2008) (Table 1). 
Arsenic is a metalloid element that is encoun-
tered primarily as arsenical compounds. 
Within these compounds, arsenic occurs in 
different valence states, the most common of 
which are AsIII (arsenites) and AsV (arsenates). 
Arsenic in drinking water is typically found 
in the inorganic form, either as AsIII or AsV, 
whereas arsenic in food is found in the organic 
and inorganic forms, depending on the spe-
cific food [Agency for Toxic Substances and 
Disease Registry (ATSDR) 2007; European 
Food Safety Authority (EFSA) 2009] Sources 
of arsenic contamination include natural 
deposits as well as anthropogenic sources such 
as mining and electronics manufacturing pro-
cesses and metal smelting (ATSDR 2007).
Arsenic holds the highest ranking on the 
current U.S. ATSDR 2011 substance priority 
list (ATSDR 2011b) (Table 2). ATSDR ranks 
chemicals using an algorithm that translates 
potential public health hazards into a points-
scaled system based on the frequency of 
occurrence at National Priority List (NPL) 
Superfund sites as well as toxicity and 
potential for human exposure. Arsenic tops 
the list in spite of the fact that this ranking 
does not include full consideration of exposure 
from drinking water, diet, copper-chromated 
arsenic-treated wood, coal- and wood-burning 
stoves, arsenical pesticides, and homeopathic 
remedies (ATSDR 2007, 2011b; Akter 
et al. 2005; EFSA 2009; Rose et al. 2007). 
Therefore, the threat to human health posed 
by arsenic is even greater than its top ATSDR 
ranking would suggest. In regard to toxicity, 
the International Agency for Research on 
Cancer (IARC) defines arsenic as a Group I 
known human carcinogen that also induces a 
wide array of other noncancer effects, leaving 
essentially no bodily system free from potential 
harm (ATSDR 2007; IARC 2012; National 
Research Council 2001; WHO 2008).
Here we synthesize the large body of cur-
rent research pertaining to arsenic exposure and 
health effects and emphasize the  broadening 
scope of predicted and observed impacts of 
arsenic on public health. Understanding the 
wide range of these impacts drives home the 
importance of testing drinking-water sources 
and monitoring foods for arsenic. Whereas 
municipalities test public drinking-water 
sources, private wells can go untested. Recent 
data also raise concerns for arsenic exposure 
via foods including rice and organic brown 
rice syrup [Davis et al. 2012; EFSA 2009; 
Food and Drug Administration (FDA) 2012; 
Gilbert-Diamond et al. 2011; Jackson et al. 
2012] as well as chicken feather meal prod-
ucts that are used in the human food system 
(Nachman et al. 2012).
Even as assessments of dietary exposure 
continue to unfold, drinking water remains a 
major concern for arsenic exposure. There are 
known, large-scale drinking-water contamina-
tion problems in countries such as Bangladesh 
(Ahsan et al. 2006; Argos et al. 2010, 2012; 
Smith et al. 2000b). However, chronic arsenic 
exposure is a concern in many parts of the 
world (Table 1). For example, arsenic con-
centrations in drinking water from some 
private wells in the United States are as high 
as 3,100 µg/L, which is in the range of the 
highest concentrations reported in Bangladesh 
(Nielsen et al. 2010; Yang et al. 2009). Yet 
detection of arsenic contamination even at 
these high levels remains problematic because 
it is tasteless, colorless, and odorless.
Given the large number of studies that 
address the broad range of information pro-
vided here, it is impractical to include all per-
tinent studies. Rather, we present a synthesis 
Address correspondence to M. Naujokas, MDB Inc., 
2525 Meridian Corporate Center, Suite 50, Durham, 
North Carolina 27713 USA. Telephone: (919) 794-
4700. E-mail: naujokasmf@niehs.nih.gov
M.F.N. is supported through a contract with the 
National Institute of Environmental Health Sciences 
(NIEHS) Superfund Research Program (SRP) (con-
tract GS-OOF-0001S, Health and Human Services 
order CR700013). H.A. is supported by National 
Institutes of Health and NIEHS SRP grants 
P42ES10349, RO1CA107431, and RO1CA102484. 
J.G. is supported by NIEHS SRP grant P42ES10349.
The authors declare they have no actual or potential 
competing financial interests.
Received 8 August 2012; accepted 21 December 
2012.
The Broad Scope of Health Effects from Chronic Arsenic Exposure: 
Update on a Worldwide Public Health Problem
Marisa F. Naujokas,1 Beth Anderson,2 Habibul Ahsan,3,4,5 H. Vasken Aposhian,6 Joseph H. Graziano,7 
Claudia Thompson,8 and William A. Suk2
1MDB Inc., Durham, North Carolina, USA; 2Superfund Research Program, National Institute of Environmental Health Sciences (NIEHS), 
National Institutes of Health (NIH), Department of Health and Human Services (DHHS), Research Triangle Park, North Carolina, 
USA; 3Department of Health Studies, 4Department of Human Genetics, and 5Department of Medicine, The University of Chicago, 
Chicago, Illinois, USA; 6Department of Molecular and Cellular Biology, University of Arizona, Tucson, Arizona, USA; 7Department of 
Environmental Health Sciences, Columbia University Mailman School of Public Health, New York, New York, USA; 8Susceptibility and 
Population Health Branch, Superfund Research Program, NIEHS, NIH, DHHS, Research Triangle Park, North Carolina, USA
Background: Concerns for arsenic exposure are not limited to toxic waste sites and massive 
 poison ing events. Chronic exposure continues to be a major public health problem worldwide, affect-
ing hundreds of millions of persons.
oBjectives: We reviewed recent information on worldwide concerns for arsenic exposures and pub-
lic health to heighten awareness of the current scope of arsenic exposure and health outcomes and 
the importance of reducing exposure, particularly during pregnancy and early life.
Methods: We synthesized the large body of current research pertaining to arsenic exposure and 
health outcomes with an emphasis on recent publications.
discussion: Locations of high arsenic exposure via drinking water span from Bangladesh, Chile, 
and Taiwan to the United States. The U.S. Environmental Protection Agency maximum con-
taminant level (MCL) in drinking water is 10 µg/L; however, concentrations of > 3,000 µg/L have 
been found in wells in the United States. In addition, exposure through diet is of growing concern. 
Knowledge of the scope of arsenic- associated health effects has broadened; arsenic leaves essentially 
no bodily system untouched. Arsenic is a known carcinogen associated with skin, lung, bladder, 
kidney, and liver cancer. Dermatological, developmental, neurological, respiratory, cardiovascular, 
immunological, and endocrine effects are also evident. Most remarkably, early-life exposure may be 
related to increased risks for several types of cancer and other diseases during adulthood.
conclusions: These data call for heightened awareness of arsenic-related pathologies in broader 
contexts than previously perceived. Testing foods and drinking water for arsenic, including indi-
vidual private wells, should be a top priority to reduce exposure, particularly for pregnant women 
and children, given the potential for life-long effects of developmental exposure.
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of information and cite recent studies that help 
illustrate the breadth and scope of the prob-
lems. When available, we cite current reviews 
that can serve as a resource for a more complete 
listing of relevant resources, most often focusing 
on single health issues such as cardiovascular 
disease (States et al. 2009). Detailed discussions 
of arsenic exposure and health effects can be 
found elsewhere (ATSDR 2007; EFSA 2009; 
Gibb et al. 2011; States et al. 2011).
As awareness of arsenic exposure increases, 
so should knowledge of its health effects 
because the impact of chronic arsenic exposure 
on public health is substantial. In addition to 
skin lesions and skin cancer (ATSDR 2011a; 
Sengupta et al. 2008; Smith et al. 2000a), 
neuro logical, respiratory, cardio vascular, and 
developmental effects and more are linked to 
chronic arsenic exposure (Table 3) (Argos et al. 
2012; Smith and Steinmaus 2009; States et al. 
2011). Acute poisonings still occur but are 
uncommon (Bronstein et al. 2011). Arsenic 
renders its toxicity via numerous mechanisms: 
Arsenic is genotoxic and has multiple effects 
on cellular signaling, cellular proliferation, 
DNA structure, epigenetic regulation, and 
apoptosis (Flora 2011; Ren et al. 2011; States 
et al. 2011).
A wealth of data comes from ongoing 
epidemiological studies of large populations 
exposed to a wide range of arsenic levels in 
drinking water in regions such as Taiwan, 
Bangladesh, Chile, India, and Argentina 
(Ahsan et al. 2006; Argos et al. 2012; Chen 
CL et al. 2010a; Smith et al. 2011; Yuan et al. 
2010). In Taiwan, a stable population in an 
arsenic-endemic region had been exposed to 
arsenic via drinking water since the 1900s 
[Chen CJ et al. 1988b, 1992; Gibb et al. 2011; 
Tseng 1977; U.S. Environmental Protection 
Agency (EPA) 2001; Wu et al. 1989]. In 
Bangladesh, tube wells were dug in the 1970s 
as a source of drinking water to avoid microbial 
contamination, only to later learn that the tube 
wells are contaminated with naturally occurring 
arsenic (Smith et al. 2000b). Researchers estab-
lished a cohort in Bangladesh with over 10,000 
persons enrolled as part of the Health Effects of 
Arsenic Longitudinal Study (HEALS) (Ahsan 
et al. 2006; Argos et al. 2012). Researchers 
are also studying a population in Chile where 
some cities were exposed to high concentra-
tions of arsenic for a defined, limited period 
of time (1958–1971), at which point, systems 
were installed to remove arsenic from drink-
ing water (Biggs et al. 1998). This population 
is particularly well suited for studies related to 
latency periods for chronic diseases and suscep-
tibility during development (Dauphine et al. 
2011; Liaw et al. 2008; Marshall et al. 2007; 
Yuan et al. 2010). Major findings from these 
cohorts and other studies are described in the 
 following sections.
In light of accumulated research, there 
is increasing awareness that arsenic exposure 
might be affecting more persons and contrib-
uting to more chronic disease than previously 
thought. In the HEALS cohort, approxi-
mately 21.4% of all deaths and 23.5% of 
deaths associated with chronic disease could 
be attributed to arsenic at > 10 µg/L in drink-
ing water (Argos et al. 2010). Here we present 
an overview and synthesis of recent infor-
mation on worldwide concerns for arsenic 
exposures and public health. The enormity 
of potential public health impacts is striking. 
Given this potential, testing and remediating 
arsenic in drinking water at the level of single 
private wells and reducing dietary exposure 
are critical to protecting public health.
Worldwide Concerns for 
Arsenic Exposure
Arsenic exposure is a major  environmental 
public health concern worldwide and a pri-
mary concern for exposure is via drinking 
water (Table 1). The WHO and Australia set 
or confirmed a guideline level of 10 µg/L for 
arsenic in drinking water in 2008 and 2011, 
respectively (National Health and Medical 
Research Council 2011; WHO 2008). The 
U.S. EPA promulgated that it lowered the 
maximum contaminant level (MCL) from 
50 µg/L to 10 µg/L, effective in 2002 (U.S. 
EPA 2001). In many developing coun-
tries, including Bangladesh, 50 µg/L is still 
the commonly adopted guideline, primarily 
because of difficulties in remediating arsenic 
below that level (WHO 2008). The excess 
cancer risk associated with lifetime arsenic 
exposure at water concentrations of > 10 µg/L 
is approximately 1 in 300, which is 30–300 
times higher than the cancer risks estimated 
for exposure to other known carcinogens in 
drinking water at concentrations equal to cur-
rent U.S. drinking-water standards (Smith 
et al. 2002).
What is the extent of chronic exposure 
via drinking water? The answer varies greatly 
depending on regional and local sources of 
arsenic (Table 1). For example, in Maine, the 
U.S. Geological Survey reported that 18.4% 
of wells tested had > 10 µg/L arsenic and esti-
mated that 24,000–44,000 households might 
be affected (Nielsen et al. 2010). A recent 
study predicted that 42.7% of the area of 
aquifers in the southwestern United States has 
arsenic concentrations of ≥ 10 µg/L, although 
portions of these areas are in remote regions 
(Anning et al. 2012). Of 63,000 wells tested 
in North Carolina, 1,436 (2.3%) had arsenic 
concentrations of > 10 µg/L with a maximum 
of 806 µg/L (Sanders et al. 2012). In com-
parison, in Bangladesh in 1998, shortly after 
discovery of arsenic contamination, it was esti-
mated that up to 94% of tube wells in certain 
regions and 35% of all wells in the country 
contained > 50 µg/L arsenic (Smith et al. 
2000b). In Chile, San Pedro de Atacama drew 
most of its public drinking water from the 
Vilama River, which contained approximately 
600–680 µg/L arsenic, and some homes with 
Table 2. The ATSDR 2011 substance priority list.
Rank Substance name Points CAS number
1 Arsenic 1665.5 007440-38-2
2 Lead 1529.1 007439-92-1
3 Mercury 1460.9 007439-97-6




6 Benzene 1332.0 000071-43-2
7 Cadmium 1318.7 007440-43-9
8 Polycyclic aromatic 
hydrocarbons
1282.3 130498-29-2
9 Benzo[a]pyrene 1305.7 000050-32-8
10 Benzo[b]fluoranthene 1252.4 000205-99-2
This list was generated by the ATSDR (2011) using an 
algorithm that translates potential public health hazards 
into a points-scaled system based on the frequency of 
occurrence at NPL Superfund sites and on toxicity and 
potential for human exposure.




Arsenic concentration in 
drinking water (µg/L) References
Argentina 2.0 < 1 to 7,550 Bates et al. 2004; Moore et al. 2004; 
Steinmaus et al. 2010
Bangladesh 35–77 < 10 to > 2,500 Kinniburgh and Smedley 2001
Chileb 0.4 600 to 800 Ferreccio et al. 2000; Smith et al. 1998, 2000a
China 0.5–2.0 < 50 to 4,400 Yu et al. 2007
Ghana < 0.1 < 2 to 175 Asante et al. 2007; Smedley 1996
India > 1.0 < 10 to > 800 Acharyya et al. 1999
Mexico 0.4 5 to 43 Calderón et al. 2001; Camacho et al. 2011; 
Meza et al. 2004, 2005
Taiwan NA < 1 to > 3,000 Chen et al. 2010a, 2010b
United States > 3.0 < 1 to > 3,100 Anning et al. 2012; Ayotte et al. 2003; Burgess 
et al. 2007; Nielsen et al. 2010; NRDC 2000; 
Peters 2008; Sanders et al. 2012; Thundiyil 
et al. 2007; Xue et al. 2010
Vietnam > 3.0 < 0.1 to 810 Winkel et al. 2011
Abbreviations: NA, not available; NRDC, National Resources Defense Council.
aEstimated number of persons exposed to > 10 µg/L arsenic in drinking water. Estimates were obtained from cited refer-
ences and usually refer to a specific city or region within each country. The actual number of exposed persons in each 
country could be higher. bThe population in one region of Chile was exposed to high levels of arsenic from 1958 to 1971, 
and studies of long-term and latent effects are ongoing.
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no public supply drew water from the San 
Pedro River, which contained 170 µg/L; in 
contrast, a town 40 km away had an aver-
age drinking-water arsenic concentration of 
15 µg/L (Hopenhayn-Rich et al. 1996).
Testing is required to determine whether a 
given source of drinking water has high levels of 
arsenic. Even if the local municipality does not 
test private wells for arsenic, test kits are avail-
able worldwide through local municipalities, 
public health offices, and commercial sources 
accessible via the Internet (Water Quality 
Association 2012; Massachusetts Department 
of Environmental Protection 2011). Hot spots 
of arsenic contamination of drinking-water 
sources can occur because of proximity to nat-
urally occurring arsenic found in certain types 
of bedrock and sediments as well as proximity 
to hazardous waste sites. Therefore, drinking-
water sources with high arsenic concentrations 
can exist in very close proximity to sources with 
low arsenic concentrations, with differences 
noted even in neighboring individual wells.
Another source of growing concern for 
arsenic exposure is through diet. For persons 
with limited exposure to arsenic via drinking 
water, diet is the major source of exposure 
(EFSA 2009). Rice, organic rice syrup, fruits, 
juices, and other grains can contain significant 
amounts of arsenic (FDA 2012; Jackson et al. 
2012; Norton et al. 2012). Furthermore, rice 
consumption has been shown to be associ-
ated with urinary arsenic levels in pregnant 
women and children (Davis et al. 2012; 
Gilbert-Diamond et al. 2011). Because of their 
level of consumption of rice products, children 
< 3 years of age are estimated to have the great-
est exposures to arsenic via diet (EFSA 2009).
Health Outcomes of Arsenic 
Exposure
Dermatological effects. Cutaneous lesions are 
one of the best-known clinical manifestations of 
chronic arsenic exposure and can occur within 
months or after several years of exposure (Das 
and Sengupta 2008; WHO 2005). Clinical 
photos of different types of arsenic- associated 
lesions are shown in Figure 1. Melanosis 
(hyperpigmentation) is considered an early 
and more common manifestation (Figure 1A), 
whereas keratosis (Figure 1B) is considered a 
sensitive marker of more advanced stages of 
arsenicosis (Das and Sengupta 2008; Sengupta 
et al. 2008). Leucomelanosis (hypopigmenta-
tion) also occurs but less frequently than mel-
anosis or keratosis. Arsenic-related melanosis 
can be diffuse or patchy, or exhibit a distinctive 
“rain drop” pattern, and these lesions often 
appear on the trunk of the body. Keratotic 
lesions tend to appear mainly on the palms 
and soles. Sudden increases in the size of kera-
totic lesions, or cracks or bleeding of lesions, 
suggest malignant transformation— often 
to squamous cell carcinoma (Figure 1C,D). 
Analyses of numerous epidemiological stud-
ies of skin lesions suggest that most persons 
with skin lesions had consumed water with 
arsenic concentrations of > 100 µg/L, although 
lesions have been reported at arsenic concen-
trations of < 50 µg/L (Argos et al. 2011; Smith 
and Steinmaus 2009). Nutritional, economic, 
and smoking status are contributing factors 
for susceptibility to skin lesions as are sex and 
age, with a greater prevalence of skin lesions in 
older men (Pierce et al. 2010). A recent report 
from the HEALS prospective study found that 
the risk of skin lesions did not decrease after 
reducing exposure for up to several years (Argos 
et al. 2011). Therefore, lesions can appear sev-
eral years after exposure diminishes. The vast 
majority of exposed individuals (even with high 
levels of chronic exposure) will not develop 
skin lesions but are still at risk of arsenic-related 
skin and internal cancers and other noncancer 
diseases (Argos et al. 2010; Chen Y et al. 2011; 
Parvez et al. 2010).
Arsenic exposure and cancer. Arsenic is a 
known carcinogen in skin, lung, bladder, liver, 
and kidney, with evidence suggesting lung can-
cer is the most common cause of arsenic-related 
mortality (IARC 2012; National Toxicology 
Program 2011). Skin cancer has long been 
associated with chronic arsenic exposure 
(ATSDR 2007; Yu et al. 2006). Squamous cell 
carcinoma in situ (Bowen’s disease; Figure 1C), 
invasive squamous cell carcinoma (Figure 1D), 
and basal cell carcinoma (Figure 1E) are the 
most common types of skin cancer associated 
with chronic arsenic exposure. Studies from 
arsenic- endemic regions of Taiwan revealed 
that the overall prevalence of skin cancer was 
10.6 per 1,000 persons and was associated 
with increased arsenic drinking-water concen-
trations (Tseng 1977) and increased urinary 
concentrations of certain arsenic metabolites 
(Tseng 2007). In the United States, where 
arsenic exposure is generally lower, signifi-
cantly increased risks for squamous cell and 
Table 3. Arsenic affects a broad range of organs and systems.
Targets Health effects References
Skin Skin lesions Argos et al. 2011; Haque et al. 2003; Smith 
et al. 2000a
Skin cancer Tseng 1977, 2007; Yu et al. 2006
Developmental processes Increased infant mortality Milton et al. 2005; Rahman et al. 2010a
Reduced birth weight Rahman et al. 2009
Altered DNA methylation of tumor 
promoter regions in cord blood and 
maternal leukocytes
Intarasunanont et al. 2012; Kile et al. 2012
Neurological impairments in children Dong and Su 2009; Hamadani et al. 2011; 
Wasserman et al. 2004, 2007
Early-life exposure associated with 
increased cancer risk as adults
Bates et al. 2004; Chen CL et al. 2010b; Liaw 
et al. 2008; Marshall et al. 2007; Su et al. 
2011; Yuan et al. 2010
Nervous system Impaired intellectual function in 
children and adults
Hamadani et al. 2011; Wasserman et al. 
2004, 2007; Dong and Su 2009
Impaired motor function Gong et al. 2011; Parvez et al. 2011
Neuropathy Vahidnia et al. 2007
Respiratory system Increased mortality from
Pulmonary tuberculosis Smith et al. 2011
Bronchiectasis Smith et al. 2006
Lung cancer Heck et al. 2009; Marshall et al. 2007; Smith 
et al. 2009
Cardiovascular system Coronary and ischemic heart disease Chen Y et al. 2011; Gong and O’Bryant 2012
Acute myocardial infarction Yuan et al. 2007
Hypertension Abhyankar et al. 2012; Abir et al. 2012
Liver, kidney, and bladder Liver cancer Chen and Ahsan 2004; Chiu et al. 2004; Liaw 
et al. 2008; Liu and Waalkes 2008
Kidney cancer Bates et al. 2004; Yuan et al. 2010
Bladder and other urinary cancers Chen et al. 2010b; Chiou et al. 2001; Gibb 
et al. 2011; Marshall et al. 2007
Immune system Altered immune-related gene 
expression and cytokine expression
Ahmed et al 2011; Andrew et al. 2008; Kile 
et al. 2012
Inflammation Ahmed et al. 2011
Increased infant morbidity from 
infectious diseases
Rahman et al. 2010b; Spivey 2011
Endocrine system Diabetes Chen et al. 2007; Del Razo et al. 2011; Islam 
et al. 2012; Jovanovic et al. 2012
Impaired glucose tolerance in 
pregnant women
Ettinger et al. 2009
Disrupted thyroid hormone, retinoic 
acid, and glucocorticoid receptor 
pathways in mice and amphibians
Barr et al. 2009; Davey et al. 2007, 2008
The list of references is not intended to be comprehensive but rather to provide examples of health effects across multiple 
bodily systems.
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basal cell carcinomas occurred in individuals in 
the top 97th percentile of toenail arsenic con-
centrations (Karagas et al. 2001), particularly 
among individuals carrying susceptible geno-
types for the nucleotide excision repair genes 
(Applebaum et al. 2007).
Chronic arsenic exposure is also associ-
ated with an increased risk of lung cancer 
(IARC 2012). In the Chilean cohort that 
was exposed to high arsenic concentrations 
in drinking water (> 850 µg/L) for a limited 
period of time (1958–1971), the peak mor-
tality rate ratio (MRR) for lung cancer was 
highest at 3.61 (95% CI: 3.13, 4.16) for men 
in 1992–1994 (Table 4), suggesting a 34- to 
36-year latency period (Marshall et al. 2007). 
Arsenic is carcinogenic in the lung regardless 
of oral or inhalation pathways of exposure, 
and it is well established that lung cancer is 
associated with exposure to > 100 µg/L arsenic 
in drinking water. However, it is unclear 
whether such an association exists for exposure 
to < 100 µg/L arsenic (Chen CL et al. 2010a; 
Heck et al. 2009; Putila and Guo 2011; 
Smith et al. 2009; Steinmaus et al. 2010).
Increasing evidence supports the hypoth-
esis that arsenic exposure can increase cancer 
risks in other organs. Increased risk of bladder 
cancer is significantly associated with increas-
ing arsenic exposure, particularly with lon-
ger exposure periods (> 40 years) and higher 
drinking-water concentrations (> 600 µg/L) 
(Chen CJ et al. 1992; Chen CL et al. 2010b; 
Chiou et al. 2001; Gibb et al. 2011; Marshall 
et al. 2007). For kidney cancer, mortality rates 
increased in a dose-dependent manner for 
drinking-water concentrations ranging from 
170 to 800 µg/L in Taiwan (Chen CJ et al. 
1988a); the MRRs at 800 µg/L were 196 for 
men and 37.0 for women. Results from other 
studies in Taiwan support this finding (Smith 
et al. 1992). More studies with larger sample 
sizes are warranted to evaluate associations at 
drinking-water concentrations of < 100 µg/L.
A causal association between arsenic expo-
sure and liver cancer, particularly liver angio-
sarcoma, was suspected as early as 1957, and 
several studies have substantiated that suspi-
cion (e.g., Liaw et al. 2008; Smith et al. 1992). 
A number of studies from the Taiwan cohort 
have demonstrated increases in liver cancer 
deaths with increasing concentrations of arsenic 
in drinking water. For example, a significant 
dose-dependent linear trend in MRRs for liver 
cancer was reported with increasing arsenic 
concentrations in drinking water ranging from 
170 to 800 µg/L (Chen CJ et al. 1988a; Wu 
et al. 1989). Links between arsenic exposure 
and liver cancer have also been supported by 
other reports (Chen CL et al. 2010b; Chen 
and Ahsan 2004; Chiu et al. 2004; Liaw et al. 
2008; Morales et al. 2000). Taking epidemio-
logical, rodent, and in vitro studies together, 
the evidence shows that the liver is a target 
organ of arsenic carcino genicity (Liu and 
Waalkes 2008).
Figure 1. Skin manifestations of chronic arsenic exposure. (A) Hyperpigmentation (melanosis); (B) hyperkeratosis (keratosis); (C) squamous cell carcinoma in situ 
(Bowen’s disease); (D) invasive squamous cell carcinoma; and (E) basal cell cancer.
Table 4. Peak mortality ratios for internal cancers and bronchiectasis in Chilean cohort studies.
Disease Reference Peak mortality ratio (95% CI) Type of mortality ratio Subpopulation with peak ratio
Lung cancer Marshall et al. 2007 3.61 (3.13, 4.16) MRR Men, 22–24 years after exposure reduction
Bladder cancer Marshall et al. 2007 13.8 (7.74, 24.5) MRR Women, 22–24 years after exposure reduction
Childhood liver cancer Liaw et al. 2008 14.1 (1.6, 126.2) MRR Girls born 1950–1957 (exposed during childhood), 0–19 years of age
Kidney cancer Yuan et al. 2010 4.37 (2.98, 6.41) MRR Women, 21–25 years after exposure reduction
9.52 (2.56, 24.4) MRR Women born 1950–1970 (exposed in utero and during childhood), 
21–25 years after exposure reduction
Bronchiectasis Smith et al. 2006 50.1 (20.0, 103) SMR Women born 1958–1970 (exposed in utero and during childhood), 
18–29 years after exposure reduction
Abbreviations: MRR, mortality rate ratio; SMR, standardized mortality ratio. For the exposed group, arsenic concentrations in drinking water were high (about 870 µg/L) between 1958 
and 1970, at which point, filtration systems were installed thereby lowering the arsenic exposure. At the time of exposure reduction, the exposed population ages ranged from  prenatal 
through adulthood.
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Other effects on multiple bodily systems. 
A multitude of other health effects are linked 
to chronic arsenic exposure. These arsenic-
 associated health problems affect nearly every 
major organ and organ system in the body 
(Table 3). A comprehensive review of the lit-
erature for these effects is beyond the scope of 
this review; therefore, this section addresses the 
broad range of harmful effects of arsenic in the 
human body and makes apparent the impact of 
arsenic-contaminated drinking water on public 
health. Taken together, the body of data drives 
home the critical importance of monitoring 
for arsenic in food sources and drinking-water 
sources, including private wells.
Significant neurological impairments are 
evident in children and adults who exhibit 
impaired cognitive abilities and motor func-
tions after arsenic exposure (Chen Y et al. 
2009; Dong and Su 2009; Gong et al. 2011; 
Hamadani et al. 2011; Parvez et al. 2011; 
Vahidnia et al. 2007; Wasserman et al. 2004, 
2007). Cognitive impairments were observed in 
children at 6 and 10 years of age (Wasserman 
et al. 2004, 2007). One recent study reported 
impairments in verbal and full-scale IQ in girls 
but not boys (Hamadani et al. 2011). In adults, 
arsenic exposure in drinking water is linked 
to significantly lower scores on tests of cogni-
tive ability as well as lower education levels 
(Gong et al. 2011). Peripheral neuropathy and 
painful muscle spasms are also known to occur 
with arsenic exposure (Sengupta et al. 2008; 
Vahidnia et al. 2007).
In addition to lung cancer, chronic arsenic 
exposure is associated with other respiratory 
system effects. Mortality from pulmonary 
tuberculosis was increased in arsenic-exposed 
individuals in the Chilean cohort (Smith 
et al. 2011). In the same cohort, increased 
mortality from bronchiectasis was significant 
for those exposed to arsenic during early life 
with a standardized mortality ratio (SMR) of 
50.1 (Table 4) (Smith et al. 2006). Reduced 
forced expiratory volume and forced vital 
capacity is associated with early-life expo-
sure to arsenic, with a magnitude of reduc-
tion similar to smoking throughout adulthood 
(Dauphine et al. 2011). Other respiratory 
symptoms include chronic cough, blood in 
the  sputum, and other breathing problems 
(Parvez et al. 2010).
The cardiovascular system is affected in 
several ways by arsenic (Abhyankar et al. 
2012; Chen Y et al. 2009, 2011; States et al. 
2009; Yuan et al. 2007). Cardiovascular effects 
include carotid atherosclerosis (Huang et al. 
2009) and ischemic heart disease (Abhyankar 
et al. 2012; Chen Y et al. 2011; States et al. 
2009). Furthermore, an association between 
hypertension and arsenic exposure is evident 
in some studies, and additional larger studies 
are needed to substantiate the link (Abhyankar 
et al. 2012; Abir et al. 2012).
Immune system effects of arsenic expo-
sure are evident in several contexts. Effects 
include altered immune-related gene expres-
sion and cytokine production in lympho cytes 
(Andrew et al. 2008; Morzadec et al. 2012) 
and in lung (Lantz et al. 2007). Arsenic is 
significantly associated with increased infant 
morbidity from infectious diseases (Rahman 
et al. 2010b). Furthermore, maternal uri-
nary arsenic during pregnancy is significantly 
associated with increased inflammation and 
reduced numbers of T cells as well as altered 
cytokine profiles in cord blood (Ahmed et al. 
2011) and reduced thymic function in infants 
(Ahmed et al. 2012).
Multiple endocrine effects of arsenic expo-
sure are suggested from studies in human and 
animal studies. These include affecting hor-
mone regulation via the retinoic acid, thyroid 
hormone, and estrogen receptors (Barr et al. 
2009; Davey et al. 2007, 2008; Ettinger et al. 
2009; Smith and Steinmaus 2009; Watson 
and Yager 2007). Increased occurrence of dia-
betes is also linked to arsenic exposure, par-
ticularly at higher doses and with exposure 
periods of > 10 years (Chen CJ et al. 2007; Del 
Razo et al. 2011; Islam et al. 2012; Jovanovic 
et al. 2012).
Varied Susceptibilities
Genetic and nutritional factors in suscepti-
bility. The variety of biological systems often 
simultaneously affected by arsenic is further 
complicated by varied individual susceptibil-
ities to its toxic effects. For example, inter-
individual variation in the ability to methylate 
arsenic is associated with differential suscepti-
bility to the effects of arsenic exposure (Hall 
and Gamble 2012; Steinmaus et al. 2010). 
Genetic polymorphisms have also been shown 
to be a contributing factor (Agusa et al. 2012; 
Ahsan et al. 2007; Applebaum et al. 2007; 
Argos et al. 2012; Pierce et al. 2012; Porter 
et al. 2010; Reichard and Puga 2010). A recent 
large, comprehensive genome-wide associa-
tion study identified specific genetic variations 
associated with risk for skin lesions as well as 
differences in arsenic metabolism (Pierce et al. 
2012). Evidence is also building that nutri-
tional factors, notably folate, appear to play 
an important role in arsenic methylation and 
elimination (Basu et al. 2011; Chen Y et al. 
2009; Gamble et al. 2007; Hall and Gamble 
2012; Pilsner et al. 2009). For example, low 
folate and hyper homocysteinemia are associ-
ated with increased risk of skin lesions (Pilsner 
et al. 2009). Together, current information 
about arsenic metabolism across individuals 
sheds light on possibilities for new strategies 
for the prevention and amelioration of the 
toxicity of arsenic.
Susceptibility during development and 
long-term latency. Adverse pregnancy and 
developmental outcomes are associated with 
early-life exposure to arsenic (Vahter 2008). 
Arsenic exposure is significantly associated 
with increased infant mortality and, in some 
studies, increased spontaneous abortion and 
stillbirth (Milton et al. 2005; Rahman et al. 
2010a; von Ehrenstein et al. 2006) as well as 
reduced birth weight (Rahman et al. 2009). 
Early-life arsenic exposure is also associated 
with neurological impairments in children 
(Hamadani et al. 2011; Parvez et al. 2011; 
Wasserman et al. 2004, 2007). For example, 
motor function in children, as well as verbal 
and full-scale IQ in girls, are both inversely 
associated with arsenic exposure (Hamadani 
et al. 2011; Parvez et al. 2011). Prenatal expo-
sure also affects the developing immune sys-
tem. Maternal urinary arsenic concentrations 
are associated with increased inflammation 
as well as altered cytokine profiles in cord 
blood and reduced thymus size and func-
tion in newborns (Ahmed et al. 2011, 2012). 
Altered immune responses are consistent with 
the observation of increased risk for lower 
respiratory infections and diarrhea in infants 
with increasing arsenic exposure (Rahman 
et al. 2010b).
The impacts of early-life arsenic exposure 
can continue into adulthood (Vahter 2008). 
Exposure during pregnancy and childhood is 
associated with an increased occurrence and/or 
severity of lung disease, cardiovascular disease, 
and cancer in childhood and later in life, with 
evidence of decades-long latency periods for 
these health conditions (Table 4) (Dauphine 
et al. 2011; Liaw et al. 2008; Marshall et al. 
2007; Smith et al. 2011; Yuan et al. 2010). 
Childhood liver cancer MRRs were 9–14 times 
higher for those exposed as young children as 
compared with controls (Liaw et al. 2008). 
Other reports of latency periods extending 
over 50 years include skin cancer (Haque et al. 
2003), urinary cancers (Bates et al. 2004; Chen 
CL et al. 2010b; Marshall et al. 2007; Su et al. 
2011), and lung cancer (Marshall et al. 2007; 
Su et al. 2011). For example, peak SMRs for 
childhood liver cancer and bronchiectasis were 
14.1 and 50.1 times higher, respectively, for 
individuals exposed to arsenic in utero and 
during childhood as compared with individu-
als exposed during other periods of their lives 
(Table 4) (Smith et al. 2006). Bladder can-
cer mortality peaked 25–36 years from the 
initiation of exposure (Marshall et al. 2007), 
and kidney cancer MRR peaked 21–25 years 
from initiation of exposure and was highest for 
women (Yuan et al. 2010). Regarding noncan-
cer health effects, early-life arsenic exposure is 
associated with increased adult mortality from 
pulmonary tuberculosis (Smith et al. 2011), 
bronchiectasis (Smith et al. 2006), and myo-
cardial infarction (Yuan et al. 2007).
Together the data indicate a sensitivity 
during development to health effects that can 
be long lasting and latent for > 50 years. The 
Naujokas et al.
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implications are profound and make it clear 
that every effort should be made to prevent 
exposure of pregnant women, women of child-
bearing age, infants, and children to arsenic in 
order to prevent a multitude of health effects, 
particularly cancer, later in life.
Conclusions
Environmental health issues are not limited to 
toxic waste sites and poisoning events: some 
deleterious exposures come from naturally 
occurring substances, such as arsenic often 
found in drinking water. Arsenic affects mul-
tiple biological systems, sometimes years or 
decades after exposure reductions. Studies that 
reveal the complex nature of the origins and 
toxicity of arsenic highlight the importance 
of heightened awareness of arsenic-related 
health effects in broader contexts than previ-
ously perceived. In spite of current efforts, 
over 200 million persons globally are at risk 
of arsenic exposure at levels of concern for 
human health. Although specific regulatory 
levels might be debatable, all would agree that 
minimizing arsenic exposure is the best solu-
tion, especially prenatal and early-life exposure. 
Therefore, testing drinking water for arsenic is 
particularly important for pregnant women 
and women of childbearing age, given the 
potential for neurological and other lifelong 
effects of early-life exposure. The return on the 
investment can be substantial when measured 
in the reduced incidence of chronic disease 
and reduced rates of cancer worldwide.
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